Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.

A Decade of SG&A: Bristol-Myers Squibb vs. Gilead Sciences

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Bristol-Myers Squibb and Gilead Sciences have demonstrated distinct approaches to managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bristol-Myers Squibb's SG&A expenses surged by approximately 36%, peaking in 2022. This reflects their aggressive expansion and marketing strategies. In contrast, Gilead Sciences saw a more moderate increase of around 104% over the same period, indicating a steady investment in administrative efficiency and sales force expansion.

The year 2020 marked a significant leap for both companies, with Bristol-Myers Squibb's expenses jumping by 58% compared to 2019, likely due to strategic acquisitions and increased marketing efforts. Meanwhile, Gilead Sciences experienced a 17% rise, aligning with their focus on expanding their therapeutic portfolio. These trends highlight the dynamic nature of SG&A management in the pharmaceutical sector.